5.3.3 Diagnostics Moves Out of the Hospital
5.3.4 Disruption Looms
6 PCR Recent Developments
6.1.1 Importance of These Developments
6.1.2 How to Use This Section
6.2 Bio Molecular Systems Gets Approval for Portable PCR Cycler
6.3 Roche Acquires GenMark
6.5 Nuclein Closes $14M in Funding
6.6 WuXi Diagnostics Closes $150M Series B Financing Round
6.7 Visby Medical to develop rapid Flu-COVID PCR test
6.8 Thermo Fisher to acquire Mesa Biotech
6.9 Scope Fluidics Secures €6.2M Supporting Rapid MDx
6.10 SARS- Testing Demand to Continue Through 2022, and Beyond
6.11 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
6.12 Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR
6.13 Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition
6.14 HelixBind Receives $3M NIH Grant to Expand Infection Dx Platform
4.3.3 Diagnostics Moves Out of the Hospital
4.3.4 Disruption Looms
5. PCR Recent Developments
5.1.1 Importance of These Developments
Scope Fluidics Secures €6.2M Supporting Rapid MDx
Quidel Expects SARS-CoV-2 Testing Demand to Continue Through 2022, and Beyond
Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR
Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition
HelixBind Receives $3M NIH Grant to Expand Bloodstream Infection Dx Platform
Israel s Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays
Thermo Fisher Sees Many Complementary Offerings in Qiagen Combination
DxTerity Gets CE Mark for At-Home Blood Sample Collection Device
Fetal Cell-Based NIPT by Droplet Digital PCR Demonstrated in Japanese Pilot Study
COVID-19 Point of Care Testing: The LumiraDx Platform, Upcoming Webinar Hosted by Xtalks
Share Article
In this free webinar, the featured speaker will discuss how the LumiraDx point of care diagnostic platform is able to uniquely combine sensitivity with speed, presenting actionable test results in minutes. The clinical performance of the LumiraDx SARS-CoV-2 Antigen Test and correlation with patient infectivity will be outlined. The SARS-CoV-2 Antibody Test (CE marked) which allows practitioners to test for antigen and antibody results on a single platform will also be introduced.
We will also share details on the development of the test that led to the fastest, most sensitive SARS-CoV-2 antigen point of care test currently commercially available.
„Finanzwirtschaftliche Risiken : NRW ist noch skeptisch gegenüber Kölner Klinikverbund ksta.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksta.de Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The market has just gotten started with a handful of small startup companies. Expect the big players to start taking notice.
CRISPR is not just about changing genes. CRISPR identifies unique genetic material instantly, accurately and cheaply. A whole new world of identification and diagnostics opens up. Find out exactly what kind of cold or flu you have. Find out exactly what kind of fish you are eating. Instantly detect the presence of unwelcome bacteria, anywhere. A new COVID test is already available.
Will this disruptive technology change the world of In Vitro Diagnostics? What is the impact on Clinical Laboratories? How will social norms be affected?